Clinical Trial Update: Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME [Phase 2]

View source ↗

Summary

Phase 2 study update on the safety, tolerability, and pharmacokinetics of subcutaneous D-4517.2 in participants with neovascular age-related macular degeneratio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• D-4517.2

Snippet

Sponsor: Ashvattha Therapeutics, Inc. | Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | Phase 2 | Status: ACTIVE_NOT_RECRUITING